Randomized clinical trial evaluating ertugliflozin
| Study name | Sample | Duration | Outcome | Adverse drug events | Reference | |
|---|---|---|---|---|---|---|
| Common | Uncommon | |||||
| Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) | 8,246 participants | 3.5 years | Ertugliflozin was determined to be as effective as a placebo in relation to the combined outcome of cardiovascular death, non-fatal heart attack, or non-fatal stroke, within the established non-inferiority margin | Urinary tract infection, symptomatic hypoglycemia | Male and female mycotic infection of genitals, severe hypoglycemia, hypovolemia, acute kidney injury, pancreatitis, diabetic ketoacidosis, fracture, amputation | [79] |
| Evaluation of Ertugliflozin effIcacy and Safety (VERTIS FACTORIAL) | 1,233 participants | 52 weeks | When administered alongside metformin in patients with poorly managed type 2 diabetes, the combined use of ertugliflozin and sitagliptin resulted in superior glycaemic control over 52 weeks compared to each medication alone | Genital mycotic infections, urinary tract infection | hypovolemia, hypoglycemia | [80] |